SCHEMBL733159

SCHEMBL733159

COC(=O)c1cc(Br)cnc1Cl

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 20/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16077093 0.89 OPRK1 (0.40) OPRK1
SCHEMBL20872624 0.82 OPRK1 (0.51) OPRK1
SCHEMBL30816026 0.82 OPRK1 (0.48) OPRK1
SCHEMBL473981 0.82 OPRK1 (0.48) OPRK1
SCHEMBL2782609 0.82 OPRK1 (0.48) OPRK1
SCHEMBL28526753 0.82 ATR (0.38) OPRK1
SCHEMBL28535766 0.82 OPRK1 (0.48) OPRK1
SCHEMBL31368194 0.81 CA12 (0.49)
SCHEMBL20889335 0.81 OPRK1 (0.50) OPRK1
SCHEMBL1886755 0.81 OPRK1 (0.50) OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112778305-B Pyridopyrimidinone compound and preparation method and application thereof 山东大学 2021-11-09 CN claimed
CN-112778305-A Pyridopyrimidone compounds and preparation method and application thereof 山东大学 2021-05-11 CN claimed
EP-4105216-B1 DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GENFLEET THERAPEUTICS SHANGHAI INC (CN) 2026-05-20 EP disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
EP-4076460-B1 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
US-20260015325-A1 ALKOXY HETEROARYL- CARBOXAMIDE OR THIOAMIDE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2026-01-15 US disclosed
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 LIEBER INST INC (US) 2026-01-01 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
EP-4646402-A1 GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2025-11-12 EP disclosed
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists Nimbus Saturn, Inc. (US) 2025-11-11 US disclosed
US-12441730-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2025-10-14 US disclosed
US-20050203081-A1 Inhibitors of protein tyrosine phosphatase 1B WYETH 2005-09-15 US disclosed
WO-2005081960-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B WYETH (US) 2005-09-09 WO disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed
EP-0265126-B1 Process for the preparation of fused pyridine compounds UNIV PRINCETON (US) 1994-04-13 EP disclosed
US-4988813-A Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1991-01-29 US disclosed
US-4902796-A 6-alkenyl and ethynyl derivatives of 2-amino-4-hydroxypyrido[2,3-d]pyrimidines THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1990-02-20 US disclosed
US-4818819-A Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1989-04-04 US disclosed
EP-0265126-A2 Process for the preparation of fused pyridine compounds THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1988-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 OPRK1 991/4885
US-20050203081-A1 Inhibitors of protein tyrosine phosphatase 1B PTPRS, PTPRO, PTPRM OPRK1 4754/4885
US-20260001861-A1 PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 SCN8A, SCN1A, SCN1B OPRK1 257/4885
US-20260015325-A1 ALKOXY HETEROARYL- CARBOXAMIDE OR THIOAMIDE COMPOUNDS CYCS, CBR3, CBR1 OPRK1 975/4885
US-12466841-B2 Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists PDXK, HIPK1, HIPK3 OPRK1 283/4885
US-12441730-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT3 OPRK1 3553/4885
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 OPRK1 23/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 OPRK1 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.